Antipodes Partners’s UiPath PATH Stock Holding History

Antipodes Partners’s Portfolio PATH Stock Details PATH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,459	Closed	-$25K	–	77
2023 Q1	$25K	Sell	1,459 -476	-25%	-$7.19K	﹤0.01%	63
2022 Q4	$24K	Buy	+1,935	New	+$23.9K	﹤0.01%	64
2022 Q3	–	Sell	-2,035,023	Closed	-$37M	–	49
2022 Q2	$37M	Buy	+2,035,023	New	+$38M	1.54%	27

Other funds holding PATH

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AGFIA

Accel Growth Fund IV Associates Palo Alto, California $58.7M AUM 25.19% 1-Year Est. Return

Antipodes Partners's PATH Position: Q2 2023 in Review

Antipodes Partners sold out of UiPath (PATH) in Q2 2023, closing a stake of 1,459 shares — an estimated $25K sold.

Antipodes Partners first reported a position in PATH in Q2 2022 and held it in 3 quarters. The position peaked at $37M in Q2 2022. 411 funds tracked by Wall St. Rank hold PATH as of Q2 2023.

Antipodes Partners reported no remaining UiPath position as of Q2 2023 after selling out during the quarter.
Antipodes Partners sold 1,459 UiPath shares in Q2 2023, an estimated $25K.
Antipodes Partners first reported a position in UiPath in Q2 2022 and held it in 3 quarters.
Antipodes Partners's UiPath position peaked at $37M in Q2 2022.
411 funds tracked by Wall St. Rank held UiPath as of Q2 2023.

Based on Antipodes Partners's 13F filing for Q2 2023, filed 25 Jul 2023.